Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte Spins Off From BioTime

NEW YORK (GenomeWeb) – OncoCyte said today that it has spun off as a publicly traded company from BioTime and has begun trading on the NYSE MKT under the symbol OCX.

On Dec. 31, BioTime distributed approximately 4.75 million shares of OncoCyte common stock to its shareholders in the ratio of one share of OncoCyte stock for every 20 BioTime common shares owned. There are now 25.4 million shares outstanding of OncoCyte, of which BioTime owns 58.55 percent.

Based in Alameda, California, OncoCyte focuses primarily on developing non-invasive blood- and urine-based diagnostic tests for the early detection of cancer. The company is developing tests for confirmatory diagnosis of lung, bladder, and breast cancer using proprietary sets of gene and protein markers.

In August, OncoCyte said that it had expanded an agreement with the Wistar Institute to develop a diagnostic test for the early detection of lung cancer using gene expression biomarkers discovered at Wistar.

"Becoming a publicly traded company is a key milestone in our development," OncoCyte CEO William Annett said in a statement. "We will continue to leverage the team's diagnostics, commercial, and public company expertise to achieve significant milestones in 2016 with the goal of maximizing shareholder value. These milestones will include preparation for the commercial launch of our first product, which, subject to the successful completion of our R&D program, will be a confirmatory diagnostic test for lung cancer."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.